Détail de l'auteur
Documents disponibles écrits par cet auteur
trié(s) par (Pertinence décroissant(e), Date de parution décroissant(e), Date de parution décroissant(e), Système de projection du document croissant(e)) Mettre toutes les notices dans le panier Faire une suggestion Ajouter un critère de recherche
Temporary Reduction of Membrane CD4 with the Antioxidant MnTBAP Is Sufficient to Prevent Immune Responses Induced by Gene Transfer
Da Rocha S, Bigot J, Onodi F, et al.
Molecular therapy. Methods & clinical development, 2019, 14, p 285
An AAV-SGCG Dose-Response Study in a gamma-Sarcoglycanopathy Mouse Model in the Context of Mechanical Stress.
Israeli D, Cosette J, Corre G, et al.
Molecular therapy. Methods & clinical development, 2019, 13, p 494
Circulating miRNAs are generic and versatile therapeutic monitoring biomarkers in muscular dystrophies
Israeli D, Poupiot J, Amor F, et al.
Scientific Reports, 2016, 6
Serum proteomic profiling reveals fragments of MYOM3 as potential biomarkers for monitoring the outcome of therapeutic interventions in muscular dystrophies.
Rouillon J, Poupiot J, Zocevic A, et al.
Human molecular genetics, 2015, Epub
Restriction of calpain3 expression to the skeletal muscle prevents cardiac toxicity and corrects pathology in a murine model of limb-girdle muscular dystrophy
Roudaut C, Le Roy F, Suel L, et al.
Circulation, 2013, 128, 10, p. 1094-1104
Prolonged gene expression in muscle is achieved without active immune tolerance using MicrorRNA 142.3p-regulated rAAV gene transfer
Boisgerault F, Gross DA, Ferrand M, et al.
Human gene therapy, 2013, 24, 4, p. 393-405
Distinctive serum miRNA profile in mouse models of striated muscular pathologies
Vignier N, Amor F, Fogel P, et al.
PLoS ONE, 2013, 8, 2, e55281, 14 p.
Rescue of sarcoglycan mutations by inhibition of endoplasmic reticulum quality control is associated with minimal structural modifications
Soheili T, Gicquel E, Poupiot J, et al.
Human mutation, 2011, 33, 2, p. 429-439
Methods for noninvasive monitoring of muscle fiber survival with an AAV vector encoding the mSEAP reporter gene
Poupiot J, Ausseil J, Richard I
2011, p. 63-74
AAV-mediated delivery of a mutated myostatin propeptide ameliorates calpain 3 but not alpha-sarcoglycan deficiency
Bartoli M, Poupiot J, Vulin A, et al.
Gene therapy, 2007, 14, 9, p. 733-740
A third of LGMD2A biopsies have normal calpain 3 proteolytic activity as determined by an in vitro assay
Milic A, Daniele N, Lochmuller H, et al.
Neuromuscular disorders : NMD, 2007, 17, 2, p. 148-156
Phenotypic correction of alpha-sarcoglycan deficiency by intra-arterial injection of a muscle-specific serotype 1 rAAV vector
Fougerousse F, Bartoli M, Poupiot J, et al.
Molecular therapy, 2007, 15, 1, p. 53-61
Safety and efficacy of AAV-mediated calpain 3 gene transfer in a mouse model of limb-girdle muscular dystrophy type 2A
Bartoli M, Roudaut C, Martin S, et al.
Molecular therapy, 2006, 13, 2, p. 250-259
Noninvasive monitoring of therapeutic gene transfer in animal models of muscular dystrophies
Bartoli M, Poupiot J, Goyenvalle A, et al.
Gene therapy, 2006, 13, 1, p. 20-28
Non invasive demonstration of muscle recovery after AAV transfer of therapeutic DNA in mdx and alpha-sarcoglycan-null mutant mice using murine secreted alkaline phosphatase as reporter (abstract : congrès international de Myologie, 2005)
Bartoli M, Poupiot J, Goyenvalle A, et al.
Congrès : Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France)
2005, p. 272
A titin anchored signalling pathway involved in muscle hypertrophy is potentially regulated by calpain 3 (abstract : congrès international de Myologie, 2005)
Laure L, Suel-Petat L, Bourg Alibert N, et al.
Congrès : Congrès international de myologie 2005 (International Congress of Myology 2005; 9-13 mai 2005; Nantes, France)
2005, p. 230
HLA-A*0201-restricted cytolytic responses to the rtTA transactivator dominant and cryptic epitopes compromise transgene expression induced by the tetracycline on system
Ginhoux F, Turbant S, Gross DA, et al.
Current opinion in molecular therapeutics, 2004, 10, 2, p. 279-289
